Authors’ Reply to the Letter to the Editor by Daniel M. Green
Authors:
Jeffrey S. Dome
Jeffrey S. DomeCenter for Cancer and Blood Disorders, Children’s National Hospital, and George Washington University School of Medicine and Health Sciences, Washington, DC
DomeJS, MullenEA, DixDB, et al.Impact of the first generation of Children’s Oncology Group clinical trials on clinical practice for Wilms tumor. J Natl Compr Canc Netw2021;19:978–985.
DomeJS, MullenEA, DixDB, Impact of the first generation of Children’s Oncology Group clinical trials on clinical practice for Wilms tumor. J Natl Compr Canc Netw 2021;19:978–985.3441670510.6004/jnccn.2021.7070)| false
GreenDM. Augmentation of therapy for combined loss of heterozygosity 1p and 16q in favorable histology Wilms tumor. J Clin Oncol 2020;38:772–773.3195149210.1200/JCO.19.02479)| false
DixDB, SeibelNL, ChiYY, et al.Treatment of stage IV favorable histology Wilms tumor with lung metastases: a report from the Children’s Oncology Group AREN0533 study. J Clin Oncol2018;36:1564–1570.
DixDB, SeibelNL, ChiYY, Treatment of stage IV favorable histology Wilms tumor with lung metastases: a report from the Children’s Oncology Group AREN0533 study. J Clin Oncol 2018;36:1564–1570.10.1200/JCO.2017.77.193129659330)| false
GrundyPE, GreenDM, DirksAC, et al.Clinical significance of pulmonary nodules detected by CT and not CXR in patients treated for favorable histology Wilms tumor on national Wilms tumor studies-4 and -5: a report from the Children’s Oncology Group. Pediatr Blood Cancer2012;59:631–635.
GrundyPE, GreenDM, DirksAC, Clinical significance of pulmonary nodules detected by CT and not CXR in patients treated for favorable histology Wilms tumor on national Wilms tumor studies-4 and -5: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2012;59:631–635.10.1002/pbc.24123)| false
DixDB, FernandezCV, ChiYY, et al.Augmentation of therapy for combined loss of heterozygosity 1p and 16q in favorable histology Wilms tumor: a Children’s Oncology Group AREN0532 and AREN0533 study report. J Clin Oncol2019;37:2769–2777.
DixDB, FernandezCV, ChiYY, Augmentation of therapy for combined loss of heterozygosity 1p and 16q in favorable histology Wilms tumor: a Children’s Oncology Group AREN0532 and AREN0533 study report. J Clin Oncol 2019;37:2769–2777.3144946810.1200/JCO.18.01972)| false
GreenDM, CottonCA, MalogolowkinM, et al.Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: a report from the National Wilms Tumor Study Group. Pediatr Blood Cancer2007;48:493–499.
GreenDM, CottonCA, MalogolowkinM, Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: a report from the National Wilms Tumor Study Group. Pediatr Blood Cancer 2007;48:493–499.10.1002/pbc.20822)| false
MalogolowkinM, CottonCA, GreenDM, et al.Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer2008;50:236–241.
MalogolowkinM, CottonCA, GreenDM, Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer 2008;50:236–241.10.1002/pbc.21267)| false
MullenEA, ChiYY, HibbittsE, et al.Impact of surveillance imaging modality on survival after recurrence in patients with favorable-histology Wilms tumor: a report from the Children’s Oncology Group [published online October 18, 2020]. J Clin Oncol, doi: 10.1200/JCO.18.00076
MullenEA, ChiYY, HibbittsE, Impact of surveillance imaging modality on survival after recurrence in patients with favorable-histology Wilms tumor: a report from the Children’s Oncology Group [published online October 18, 2020]. J Clin Oncol, doi: 10.1200/JCO.18.00076)| false